About Pacira Pharmaceuticals (NASDAQ:PCRX)
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560
Debt
Debt-to-Equity Ratio0.99%
Current Ratio6.96%
Quick Ratio6.22%
Price-To-Earnings
Trailing P/E Ratio-61.12
Forward P/E Ratio-69.51
P/E GrowthN/A
Sales & Book Value
Annual Sales$286.63 million
Price / Sales5.03
Cash Flow$0.0612 per share
Price / Cash579.57
Book Value$6.89 per share
Price / Book5.15
Profitability
EPS (Most Recent Fiscal Year)($0.58)
Net Income$-42,610,000.00
Net Margins-14.87%
Return on Equity-8.55%
Return on Assets-3.77%
Miscellaneous
Employees489
Outstanding Shares40,710,000
Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions
What is Pacira Pharmaceuticals' stock symbol?
Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."
How were Pacira Pharmaceuticals' earnings last quarter?
Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) released its earnings results on Wednesday, February, 28th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.46. The business had revenue of $79.08 million for the quarter, compared to the consensus estimate of $79.06 million. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The business's quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.09 earnings per share. View Pacira Pharmaceuticals' Earnings History.
When is Pacira Pharmaceuticals' next earnings date?
What price target have analysts set for PCRX?
20 equities research analysts have issued twelve-month price targets for Pacira Pharmaceuticals' stock. Their predictions range from $27.00 to $80.00. On average, they anticipate Pacira Pharmaceuticals' share price to reach $44.50 in the next twelve months. View Analyst Ratings for Pacira Pharmaceuticals.
What are Wall Street analysts saying about Pacira Pharmaceuticals stock?
Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Pacira fourth-quarter 2017 earnings surpassed estimates while revenues were at par with them. Pacira’s top line mainly comprises contribution from its marketed product Exparel which generated sales of $282.9 million in 2017, up 6.4%. The company’s efforts to expand Exparel's label are encouraging. Pacira remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. However, the company is heavily dependent on Exparel for growth. In February 2018, the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee reviewed the company’s sNDA, and voted six to four against approval of the expanded indication. We believe that this is a concern for the company. However, the company however remains confident and will keep an open dialogue with the FDA to define the best next steps for expanding the Exparel indication." (3/6/2018)
- 2. Canaccord Genuity analysts commented, "We’re looking for more than two months of data showing solid growth before we become positive on the potential for a meaningful inflection in Exparel use trends, especially with a noisy October that may have benefited from hurricane-related deferred procedures that negatively impacted September volumes. We remain HOLD rated on PCRX shares." (12/29/2017)
- 3. Cowen Inc analysts commented, "Nerve block data for Exparel is anticipated within the next month, and our consultants." (7/14/2017)
Who are some of Pacira Pharmaceuticals' key competitors?
Some companies that are related to Pacira Pharmaceuticals include Clovis Oncology (CLVS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD), Evotec A.G. (EVTCY), Puma Biotechnology (PBYI), Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Akorn (AKRX), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Heron Therapeutics (HRTX), AnaptysBio (ANAB) and Intercept Pharmaceuticals (ICPT).
Who are Pacira Pharmaceuticals' key executives?
Pacira Pharmaceuticals' management team includes the folowing people:
- Mr. David M. Stack, Chairman and Chief Exec. Officer (Age 68)
- Mr. Charles A. Reinhart III, Chief Financial Officer (Age 57)
- Dr. Scott Braunstein, Chief Operating Officer (Age 55)
- Ms. Kristen Williams J.D., Chief Admin. Officer, Gen. Counsel and Sec. (Age 44)
- Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 39)
Has Pacira Pharmaceuticals been receiving favorable news coverage?
Media coverage about PCRX stock has trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pacira Pharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also gave press coverage about the company an impact score of 44.49 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Pacira Pharmaceuticals' major shareholders?
Pacira Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include PARTNER FUND MANAGEMENT, L.P. (6.00%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.
How do I buy shares of Pacira Pharmaceuticals?
Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pacira Pharmaceuticals' stock price today?
One share of PCRX stock can currently be purchased for approximately $35.45.
How big of a company is Pacira Pharmaceuticals?
Pacira Pharmaceuticals has a market capitalization of $1.45 billion and generates $286.63 million in revenue each year. The company earns $-42,610,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Pacira Pharmaceuticals employs 489 workers across the globe.
How can I contact Pacira Pharmaceuticals?
Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]
MarketBeat Community Rating for Pacira Pharmaceuticals (PCRX)
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pacira Pharmaceuticals (NASDAQ:PCRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
20 Wall Street analysts have issued ratings and price targets for Pacira Pharmaceuticals in the last 12 months. Their average twelve-month price target is $44.50, suggesting that the stock has a possible upside of 25.53%. The high price target for PCRX is $80.00 and the low price target for PCRX is $27.00. There are currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.35 | 2.35 | 2.45 | 2.56 |
| Ratings Breakdown: | 1 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
9 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $44.50 | $45.00 | $49.50 | $52.6154 |
| Price Target Upside: | 25.53% upside | 46.72% upside | 26.60% upside | 59.20% upside |
Pacira Pharmaceuticals (NASDAQ:PCRX) Consensus Price Target History
Pacira Pharmaceuticals (NASDAQ:PCRX) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Pacira Pharmaceuticals (NASDAQ:PCRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Pacira Pharmaceuticals (NASDAQ PCRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.60%
Pacira Pharmaceuticals (NASDAQ PCRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/10/2018 | David M. Stack | CEO | Sell | 28,885 | $40.19 | $1,160,888.15 | |  |
| 12/15/2017 | Lauren Bullaro Riker | VP | Sell | 340 | $43.70 | $14,858.00 | | |
| 11/20/2017 | James B. Jones | SVP | Sell | 850 | $41.11 | $34,943.50 | | |
| 11/17/2017 | Kristen Marie Williams | CAO | Sell | 10,000 | $40.00 | $400,000.00 | 23,455 | |
| 11/15/2017 | David M Stack | CEO | Sell | 58,885 | $38.34 | $2,257,650.90 | 159,164 | |
| 11/10/2017 | Mark A Kronenfeld | Director | Buy | 1,000 | $41.60 | $41,600.00 | 6,795 | |
| 8/22/2017 | Paul J Hastings | Director | Sell | 1,044 | $36.15 | $37,740.60 | 3,518 | |
| 8/15/2017 | David M Stack | CEO | Sell | 28,885 | $36.37 | $1,050,547.45 | 159,164 | |
| 8/15/2017 | Kristen Marie Williams | CAO | Sell | 3,461 | $36.75 | $127,191.75 | 21,312 | |
| 8/8/2017 | Mark Froimson | Director | Buy | 100 | $37.13 | $3,713.00 | 100 | |
| 6/5/2017 | David M Stack | CEO | Sell | 4,311 | $43.32 | $186,752.52 | 59,559 | |
| 6/5/2017 | James S Scibetta | President | Sell | 1,966 | $43.32 | $85,167.12 | 25,118 | |
| 6/5/2017 | Kristen Marie Williams | CAO | Sell | 1,877 | $43.32 | $81,311.64 | 13,773 | |
| 6/5/2017 | Lauren Bullaro Riker | VP | Sell | 601 | $43.32 | $26,035.32 | | |
| 6/5/2017 | Scott Braunstein | SVP | Sell | 768 | $43.32 | $33,269.76 | 9,982 | |
| 5/15/2017 | James S Scibetta | President | Sell | 20,000 | $51.20 | $1,024,000.00 | 47,084 | |
| 5/15/2017 | Kristen Marie Williams | CAO | Sell | 21,041 | $50.86 | $1,070,145.26 | 18,775 | |
| 1/17/2017 | David M. Stack | CEO | Sell | 15,000 | $38.41 | $576,150.00 | | |
| 1/17/2017 | James S Scibetta | President | Sell | 20,000 | $38.53 | $770,600.00 | 29,457 | |
| 8/15/2016 | David M. Stack | CEO | Sell | 15,000 | $45.32 | $679,800.00 | | |
| 8/15/2016 | James S. Scibetta | President | Sell | 25,000 | $45.21 | $1,130,250.00 | | |
| 6/7/2016 | Lauren Bullaro Riker | VP | Sell | 938 | $47.66 | $44,705.08 | 5,945 | |
| 6/6/2016 | Kristen Marie Williams | CAO | Sell | 600 | $47.20 | $28,320.00 | 6,900 | |
| 6/6/2016 | Lauren Bullaro Riker | VP | Sell | 321 | $47.20 | $15,151.20 | 5,945 | |
| 6/6/2016 | Mark A Kronenfeld | Director | Sell | 900 | $46.95 | $42,255.00 | 2,950 | |
| 4/15/2016 | David M Stack | CEO | Sell | 25,000 | $64.14 | $1,603,500.00 | 25,285 | |
| 1/29/2016 | Scott Braunstein | SVP | Buy | 2,000 | $58.92 | $117,840.00 | 2,000 | |
| 1/27/2016 | James B Jones | SVP | Buy | 500 | $62.50 | $31,250.00 | 1,500 | |
| 1/15/2016 | David M. Stack | CEO | Sell | 15,000 | $63.84 | $957,600.00 | 285 | |
| 1/12/2016 | James B Jones | SVP | Buy | 1,000 | $66.00 | $66,000.00 | 1,000 | |
| 1/12/2016 | John P Phd Longenecker | Director | Buy | 300 | $66.55 | $19,965.00 | 2,300 | |
| 10/15/2015 | David M. Stack | CEO | Sell | 15,000 | $37.57 | $563,550.00 | 176 | |
| 9/11/2015 | James S Scibetta | CFO | Buy | 5,000 | $61.37 | $306,850.00 | 10,504 | |
| 8/17/2015 | Paul J Hastings | Director | Sell | 3,000 | $60.02 | $180,060.00 | | |
| 7/15/2015 | David M Stack | CEO | Sell | 15,000 | $67.78 | $1,016,700.00 | | |
| 4/15/2015 | David M Stack | CEO | Sell | 25,000 | $90.50 | $2,262,500.00 | | |
| 4/10/2015 | Paul J Hastings | Director | Sell | 2,500 | $88.00 | $220,000.00 | | |
| 3/16/2015 | Lauren Bullaro Riker | Director | Sell | 5,000 | $95.34 | $476,700.00 | | |
| 3/13/2015 | Gary W Pace | Director | Buy | 1,000 | $93.83 | $93,830.00 | | |
| 2/6/2015 | James S Scibetta | CFO | Sell | 15,000 | $111.22 | $1,668,300.00 | | |
| 1/15/2015 | David M Stack | CEO | Sell | 15,000 | $97.52 | $1,462,800.00 | | |
| 1/12/2015 | Paul J Hastings | Director | Sell | 2,500 | $94.06 | $235,150.00 | | |
| 12/29/2014 | John P Phd Longenecker | Director | Sell | 1,000 | $93.32 | $93,320.00 | | |
| 12/5/2014 | Dennis L Winger | Director | Buy | 2,645 | $94.54 | $250,058.30 | | |
| 11/7/2014 | James S Scibetta | CFO | Sell | 15,000 | $87.18 | $1,307,700.00 | | |
| 11/7/2014 | Taunia Markvicka | SVP | Buy | 230 | $86.62 | $19,922.60 | | |
| 10/10/2014 | Paul J Hastings | Director | Sell | 2,500 | $94.87 | $237,175.00 | | |
| 9/29/2014 | John P Phd Longenecker | Director | Sell | 1,000 | $96.40 | $96,400.00 | | |
| 8/29/2014 | Andreas Wicki | Director | Sell | 21,494 | $108.11 | $2,323,716.34 | | |
| 8/27/2014 | Andreas Wicki | Director | Sell | 55,813 | $108.08 | $6,032,269.04 | | |
| 8/26/2014 | Andreas Wicki | Director | Sell | 24,207 | $108.11 | $2,617,018.77 | | |
| 8/25/2014 | Andreas Wicki | Director | Sell | 30,000 | $108.07 | $3,242,100.00 | | |
| 8/11/2014 | Andreas Wicki | Director | Sell | 150,000 | $101.25 | $15,187,500.00 | | |
| 8/8/2014 | James S Scibetta | CFO | Sell | 15,000 | $99.63 | $1,494,450.00 | | |
| 8/7/2014 | Gary Patou | Insider | Sell | 20,000 | $100.26 | $2,005,200.00 | | |
| 7/15/2014 | David M Stack | CEO | Sell | 15,000 | $86.75 | $1,301,250.00 | | |
| 7/14/2014 | Gary Patou | Insider | Sell | 29,700 | $86.96 | $2,582,712.00 | | |
| 7/10/2014 | Paul J Hastings | Director | Sell | 2,500 | $84.41 | $211,025.00 | | |
| 6/6/2014 | Andreas Wicki | Director | Sell | 67,900 | $82.62 | $5,609,898.00 | | |
| 6/3/2014 | Andreas Wicki | Director | Sell | 68,000 | $80.69 | $5,486,920.00 | | |
| 5/27/2014 | Andreas Wicki | Director | Sell | 64,400 | $77.93 | $5,018,692.00 | | |
| 5/21/2014 | Andreas Wicki | Director | Sell | 3,600 | $77.80 | $280,080.00 | | |
| 5/12/2014 | Gary Patou | Insider | Sell | 30,000 | $74.39 | $2,231,700.00 | | |
| 5/9/2014 | David Stack | CEO | Sell | 25,000 | $73.94 | $1,848,500.00 | 1,208 | |
| 5/9/2014 | Laura Brege | Director | Sell | 10,000 | $73.85 | $738,500.00 | | |
| 5/8/2014 | Andreas Wicki | Director | Sell | 23,220 | $75.76 | $1,759,147.20 | | |
| 5/8/2014 | James Scibetta | CFO | Sell | 15,000 | $75.05 | $1,125,750.00 | 5,000 | |
| 5/7/2014 | Andreas Wicki | Director | Sell | 44,780 | $75.78 | $3,393,428.40 | | |
| 3/28/2014 | John Phd Longenecker | Director | Sell | 1,000 | $64.63 | $64,630.00 | | |
| 3/6/2014 | Andreas Wicki | Director | Sell | 24,887 | $80.16 | $1,994,941.92 | | |
| 12/30/2013 | David Stack | CEO | Sell | 15,000 | $55.84 | $837,600.00 | 2,987 | |
| 12/30/2013 | James Scibetta | CFO | Sell | 10,000 | $55.55 | $555,500.00 | 5,000 | |
| 12/30/2013 | John Phd Longenecker | Director | Sell | 2,500 | $55.55 | $138,875.00 | | |
| 10/1/2013 | Gary Patou | Insider | Sell | 20,000 | $48.92 | $978,400.00 | | |
| 9/11/2013 | Andreas Wicki | Director | Sell | 17,783 | $37.25 | $662,416.75 | | |
| 8/14/2013 | Taunia Markvicka | VP | Sell | 14,700 | $37.00 | $543,900.00 | | |
| 7/22/2013 | Andreas Wicki | Director | Sell | 75,958 | $35.06 | $2,663,087.48 | | |
| 7/18/2013 | Andreas Wicki | Director | Sell | 25,560 | $33.45 | $854,982.00 | | |
| 7/16/2013 | Andreas Wicki | Director | Sell | 48,482 | $33.28 | $1,613,480.96 | | |
| 7/12/2013 | Taunia Markvicka | VP | Sell | 29,754 | $32.00 | $952,128.00 | | |
| 7/11/2013 | Andreas Wicki | Director | Sell | 80,000 | $31.48 | $2,518,400.00 | | |
| 7/5/2013 | Andreas Wicki | Director | Sell | 44,021 | $30.80 | $1,355,846.80 | | |
| 7/3/2013 | Andreas Wicki | Director | Sell | 114,448 | $30.21 | $3,457,474.08 | | |
| 7/2/2013 | Gary Patou | Insider | Sell | 40,000 | $29.44 | $1,177,600.00 | | |
| 6/28/2013 | David M Stack | CEO | Sell | 15,000 | $28.73 | $430,950.00 | | |
| 6/28/2013 | James S Scibetta | CFO | Sell | 10,000 | $28.05 | $280,500.00 | | |
| 6/28/2013 | John P Phd Longenecker | Director | Sell | 2,000 | $28.09 | $56,180.00 | | |
| 6/24/2013 | Fred A Middleton | Director | Sell | 75,900 | $29.13 | $2,210,967.00 | | |
| 6/20/2013 | Fred A Middleton | Director | Sell | 144,100 | $29.32 | $4,225,012.00 | | |
| 6/19/2013 | Andreas Wicki | Director | Sell | 35,407 | $29.90 | $1,058,669.30 | | |
| 6/17/2013 | Andreas Wicki | Director | Sell | 50,145 | $29.86 | $1,497,329.70 | | |
| 6/13/2013 | John Pratt | Insider | Sell | 21,032 | $30.00 | $630,960.00 | | |
| 6/13/2013 | Luke Evnin | Director | Sell | 22,746 | $30.07 | $683,972.22 | | |
| 6/12/2013 | Andreas Wicki | Director | Sell | 4,409 | $30.00 | $132,270.00 | | |
| 6/11/2013 | Andreas Wicki | Director | Sell | 11,500 | $30.00 | $345,000.00 | | |
| 6/11/2013 | John Pratt | Insider | Sell | 18,343 | $30.00 | $550,290.00 | | |
| 6/5/2013 | Andreas Wicki | Director | Sell | 15,500 | $30.26 | $469,030.00 | | |
| 6/3/2013 | Andreas Wicki | Director | Sell | 1,900 | $30.00 | $57,000.00 | | |
| 5/31/2013 | Luke Evnin | Director | Sell | 54,517 | $30.00 | $1,635,510.00 | | |
| 5/29/2013 | Luke Evnin | Director | Sell | 215,528 | $30.86 | $6,651,194.08 | | |
| 5/22/2013 | Andreas Wicki | Director | Sell | 18,471 | $30.00 | $554,130.00 | | |
| 5/20/2013 | Andreas Wicki | Director | Sell | 14,374 | $30.00 | $431,220.00 | | |
| 3/25/2013 | Andreas Wicki | Director | Sell | 290,900 | $27.95 | $8,130,655.00 | | |
(Data available from 1/1/2013 forward)
Pacira Pharmaceuticals (NASDAQ PCRX) News Headlines
| Source: |
|
Pacira Pharmaceuticals (NASDAQ:PCRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pacira Pharmaceuticals (NASDAQ:PCRX) Income Statement, Balance Sheet and Cash Flow Statement
Pacira Pharmaceuticals (NASDAQ PCRX) Stock Chart for Thursday, April, 19, 2018
Loading chart…
